Savara Inc
NASDAQ:SVRA

Watchlist Manager
Savara Inc Logo
Savara Inc
NASDAQ:SVRA
Watchlist
Price: 6.61 USD -4.48% Market Closed
Market Cap: 1.3B USD

Savara Inc
Pre-Tax Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Savara Inc
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
Savara Inc
NASDAQ:SVRA
Pre-Tax Income
-$115.6m
CAGR 3-Years
-43%
CAGR 5-Years
-11%
CAGR 10-Years
-12%
Abbvie Inc
NYSE:ABBV
Pre-Tax Income
$1.7B
CAGR 3-Years
-52%
CAGR 5-Years
-27%
CAGR 10-Years
-8%
Gilead Sciences Inc
NASDAQ:GILD
Pre-Tax Income
$9.9B
CAGR 3-Years
30%
CAGR 5-Years
41%
CAGR 10-Years
-7%
Amgen Inc
NASDAQ:AMGN
Pre-Tax Income
$8.2B
CAGR 3-Years
2%
CAGR 5-Years
0%
CAGR 10-Years
1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Pre-Tax Income
$4.4B
CAGR 3-Years
3%
CAGR 5-Years
9%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Pre-Tax Income
$5.1B
CAGR 3-Years
-5%
CAGR 5-Years
8%
CAGR 10-Years
16%
No Stocks Found

Savara Inc
Glance View

Market Cap
1.3B USD
Industry
Biotechnology

Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. The company is headquartered in Austin, Texas and currently employs 22 full-time employees. The company went IPO on 2001-06-25. The firm is focused on rare respiratory diseases. The Company’s lead program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim an inhaled formulation of recombinant human GM-CSF, is being developed for the treatment of aPAP. Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the build-up of surfactant in the alveoli or air sacs of the lungs.

SVRA Intrinsic Value
2.39 USD
Overvaluation 64%
Intrinsic Value
Price

See Also

What is Savara Inc's Pre-Tax Income?
Pre-Tax Income
-115.6m USD

Based on the financial report for Sep 30, 2025, Savara Inc's Pre-Tax Income amounts to -115.6m USD.

What is Savara Inc's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 10Y
-12%

Over the last year, the Pre-Tax Income growth was -41%. The average annual Pre-Tax Income growth rates for Savara Inc have been -43% over the past three years , -11% over the past five years , and -12% over the past ten years .

Back to Top